JODY FOWERS: Open Payments
NPI 1992915052 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$755 in 35 payments from 20 companies in 2025. Trend: 2023 $918 · 2024 $972 · 2025 $755
Food & beverage: $655Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $117 |
| ABBVIE INC. | 5 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $46 |
| Organon LLC | 3 | $41 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $31 |
| Neuronetics, Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
Products named: CAPLYTA, VRAYLAR, XIFAXAN, NEXPLANON, INGREZZA, VOQUEZNA, NEUROSTAR TMS THERAPY SYSTEM, UBRELVY.
Industry payments across UT — which companies pay providers there.
